CoNexus Cancer Care Aggressively Treats Stage III/IV Pancreatic Cancers:

CoNexus Cancer Care delivers a concentration of approved medications directly into cancerous tumors while under CT imaging guidance. ICCA physicians have treated tens of hundreds of patients.

ICCA physicians have treated lethal Stage III/IV Metastatic Pancreatic Cancers at Treatment Center in Mexico for over 40 years!

ICCA physicians use customized treatment plans unavailable to physicians within the U.S. or Canada – and if told chemotherapy is your only option, then get a second opinion from ICCA or another cancer center ASAP!

ICCA physicians have spent years perfecting CoNexus Cancer Care; a customized, multifocal treatment approach synergistically combining:

• Live Cell Tumor Profiling - Extraordinary technique to measure how cancer cells respond to a myriad of drugs combination.
• Tumor-targeted, low-dose radiation (10 sessions or less, not the normal 25 or 30 sessions in conventional medicine).
• Tumor-targeted chemotherapy, when combined with low-dose radiation, greatly enhances tumor necrosis (cell death).
• Tumor-targeted immunotherapy (a particular medicine injected directly into tumor).

CoNexus Cancer Care has been clinically shown to often surpass conventional cancer treatments, with fewer side effects and far more favorable treatment outcomes!

Why, because U.S. physicians can't or don't use many of the cutting-edge cancer therapies or a combination therein, that ICCA physicians use when treating Stage III/IV metastatic colon cancers!

Very low-dose radiation in combination with a radio-sensitizing agent (chemo agents that selectively enhance tumor cell death during concurrent radiation yet exhibit no toxicity on normal tissues).

Targeted low-dose radiation is often used by ICCA physicians to treat liver metastases in many pancreatic patients -- with even more favorable results when a chemo-based radiation sensitizing agent is used contemporaneously.

CoNexus Cancer Care tumor-targeted immunotherapy is comprised of FDA-approved compounds and substances (e.g., cytokines, haptens, etc.) that are combined, and interjected directly into the tumor tissues, eliciting an enhanced autoimmune cell response which serves to better identify evasive cancer cells and help destroy, hamper or even reverse progressive tumor growth.

Small volumes of systemic chemotherapy can be given concurrent with low-dose radiation, and; in certain follow-up circumstances – as a follow-up to confirm all microscopic cancer cells have been destroyed.

Select targeting agents are also available to destroy a specific growth factor or receptor lying within the tumor cells. These agents are usually given in combination with chemotherapy to help stop cancer cells from growing or spreading.

Angiogenesis inhibitors, which block the formation of new blood vessels, have been approved for use against pancreatic cancer spread to other parts of the body.

Live Cell Tumor Profiling
Tumor Cell profiling is very different from genomic testing which is offered by most medical centers. Genomic testing looks for mutations and other changes in each patient's gene makeup that might guide drug selection. Although the concept is appealing, in reality, a minority of patients have genetic changes that can be used for therapy. Tumor Cell profiling is a laboratory technique pioneered by our affiliate laboratory which measures how cancer cells will respond when exposed to certain drugs and drug combinations.

Most Effective and Least Toxic Treatment
Currently, hundreds of drugs, drug combinations, and targeted agents are used to treat cancers. So how does an oncologist decide which ones to use? Typically, they use established regimens developed through randomized clinical trials. These regimens are average solutions for the "average" patient. Regrettably, average treatments provide average outcomes, with the majority of patients failing to show significant improvement from these protocols.

Programmed Cell Death is the Key
Put simply, it is a real-time measure of which drugs cause your cancer cells to die, through a process called programmed cell death. By using this approach, our laboratory can determine the best drugs for each patient before ever receiving them. The selection of drugs/agents used for testing are disease-specific and based on your diagnosis and previous treatment history. Our oncologists then customize the drugs based on the results of the test. A standard panel consists of 8-16 drugs/combinations.

What We Can Do for You
Our affiliate laboratory has developed a human tumor primary culture platform for the study of drugs, biologic agents, radiation, and drug combinations. Cells isolated from surgical biopsies, peripheral blood, fluids, and bone marrow aspirates are examined for drug-induced programmed cell death. Incorporating the complexity of cell death, this platform measures both apoptotic and non-apoptotic events. The laboratory can obtain fresh, viable specimens for the isolation of micro-spheroids that have proven reflective of the clinical behavior of human tumors.